NR3C2 and chronic kidney disease: Mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone have been demonstrated to improve blood pressure control, reduce proteinuria and slow progression of CKD and reduce mortality in heart failure.39, 40, 41